Myocardial Ischemia – Pipeline Review, H2 2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Myocardial
Ischemia – Pipeline Review, H2 2017”
report has been added to Research
and Markets’
offering.

Myocardial Ischemia – Pipeline Review, H2 2017, provides comprehensive
information on the therapeutics under development for Myocardial
Ischemia (Cardiovascular), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of
key players involved in therapeutic development for Myocardial Ischemia
and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Phase III, Phase I, Preclinical
and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the
Universities portfolio in Preclinical stages comprises 2 molecules,
respectively.

Myocardial Ischemia (Cardiovascular) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Myocardial Ischemia – Overview
  3. Myocardial Ischemia – Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Myocardial Ischemia – Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Myocardial Ischemia – Companies Involved in Therapeutics Development
  • Angionetics Inc
  • Bayer AG
  • Cellmid Ltd
  • CohBar Inc
  • Lixte Biotechnology Holdings Inc
  • NoNO Inc
  • Omniox Inc
  • Pathfinder Cell Therapy Inc

For more information about this report visit https://www.researchandmarkets.com/research/g3f5rd/myocardial?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs